Type I Photosensitizer Targeting Glycans: Overcoming Biofilm Resistance by Inhibiting the Two‐Component System, Quorum Sensing, and Multidrug Efflux

Stubborn biofilm infections pose serious threats to human health due to the persistence, recurrence, and dramatically magnified antibiotic resistance. Photodynamic therapy has emerged as a promising approach to combat biofilm. Nevertheless, how to inhibit the bacterial signal transduction system and...

Full description

Saved in:
Bibliographic Details
Published in:Advanced materials (Weinheim) 2023-12, Vol.35 (52), p.e2309797-n/a
Main Authors: Xia, Feng‐Wei, Guo, Bing‐Wei, Zhao, Yu, Wang, Jia‐Li, Chen, Yuan, Pan, Xiu, Li, Xin, Song, Jia‐Xing, Wan, Yu, Feng, Shun, Wu, Ming‐Yu
Format: Article
Language:English
Subjects:
Anti-Bacterial Agents - pharmacology
biofilm resistance
Biofilms
Efflux
Glycan
glycan targeting
Homeostasis
Humans
Materials science
Membranes
Methicillin-Resistant Staphylococcus aureus
Microbial Sensitivity Tests
multidrug efflux
Osmosis
Photosensitizing Agents - pharmacology
Quorum Sensing
Signal transduction
Staphylococcus infections
type I photosensitizers
Wound healing
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Stubborn biofilm infections pose serious threats to human health due to the persistence, recurrence, and dramatically magnified antibiotic resistance. Photodynamic therapy has emerged as a promising approach to combat biofilm. Nevertheless, how to inhibit the bacterial signal transduction system and the efflux pump to conquer biofilm recurrence and resistance remains a challenging and unaddressed issue. Herein, a boric acid‐functionalized lipophilic cationic type I photosensitizer, ACR‐DMP, is developed, which efficiently generates •OH to overcome the hypoxic microenvironment and photodynamically eradicates methicillin‐resistant Staphylococcus aureus (MRSA) and biofilms. Furthermore, it not only alters membrane potential homeostasis and osmotic pressure balance due to its strong binding ability with plasma membrane but also inhibits quorum sensing and the two‐component system, reduces virulence factors, and regulates the activity of the drug efflux pump attributed to the glycan‐targeting ability, helping to prevent biofilm recurrence and conquer biofilm resistance. In vivo, ACR‐DMP successfully obliterates MRSA biofilms attached to implanted medical catheters, alleviates inflammation, and promotes vascularization, thereby combating infections and accelerating wound healing. This work not only provides an efficient strategy to combat stubborn biofilm infections and bacterial multidrug resistance but also offers systematic guidance for the rational design of next‐generation advanced antimicrobial materials. A glycan‐targeting type I photosensitizer is developed to fight against stubborn biofilms. ACR‐DMP has high extracellular polymer penetrability and overcomes the hypoxic microenvironment, which therefore efficiently eradicates biofilm in vitro and in vivo. It not only changes the membrane potential homeostasis and the osmotic pressure balance, but also inhibits quorum sensing, two‐component system, and efflux pump to conquer biofilm resistance.
ISSN:0935-9648
1521-4095
DOI:10.1002/adma.202309797